CHEMBL19020

GPTKB entity

Statements (49)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
gptkbp:approvalYear 1998
gptkbp:ATCCode gptkb:G04BE03
gptkbp:bioavailability 40%
gptkbp:brand gptkb:Revatio
gptkb:Viagra
gptkbp:CASNumber 139755-83-2
gptkbp:color blue (as Viagra tablet)
gptkbp:contraindication concurrent nitrate therapy
severe cardiovascular disorders
gptkbp:developedBy gptkb:Pfizer
gptkbp:drugClass phosphodiesterase type 5 inhibitor
gptkbp:eliminationHalfLife 3-5 hours
gptkbp:hasFirstApprovalCountry gptkb:United_States
gptkbp:hasInChIKey LZQGIZGDKIQOCX-UHFFFAOYSA-N
gptkbp:hasLogP 2.6
gptkbp:hasMolecularFormula C17H19N3O3
gptkbp:hasPatentExpiry 2013 (US)
gptkbp:hasSMILES CCCN1C2=C(C(=N1)C)N(C=N2)C3=CC(=C(C=C3)S(=O)(=O)N4CCN(CC4)C)OCC
gptkbp:hasUNII 3M7OB98Y7H
https://www.w3.org/2000/01/rdf-schema#label CHEMBL19020
gptkbp:indication erectile dysfunction
pulmonary arterial hypertension
gptkbp:IUPACName gptkb:1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction inhibits phosphodiesterase type 5 (PDE5)
gptkbp:meltingPoint 189-190°C
gptkbp:metabolism hepatic (CYP3A4, CYP2C9)
gptkbp:molecularWeight 313.35
gptkbp:pregnancyCategory gptkb:B1_(AU)
B (US)
gptkbp:proteinBinding 96%
gptkbp:PubChem_CID gptkb:CHEMBL19020
DB00203
135398744
gptkbp:routeOfAdministration oral
gptkbp:shape diamond (as Viagra tablet)
gptkbp:sideEffect headache
nasal congestion
dyspepsia
flushing
visual disturbances
gptkbp:synonym gptkb:Sildenafil
gptkbp:target gptkb:PDE6
PDE5A
gptkbp:therapeuticArea cardiology
urology
gptkbp:bfsParent gptkb:tipifarnib
gptkbp:bfsLayer 7